Compare NextEra Energy, Inc. (NEE) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NextEra Energy, Inc. vs TG Therapeutics Inc — how do they compare? NextEra Energy, Inc. trades at $85.63 (market cap $178.85B), while TG Therapeutics Inc trades at $49.8 (market cap $7.64B). The key difference: NextEra Energy, Inc. is far larger — about 23.4× TG Therapeutics Inc's market cap, and NextEra Energy, Inc. pays a 2.91% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| NEE | TGTX | |
|---|---|---|
Market Cap | $178.85B | $7.64B |
Sector | Utilities | Health |
52-Week High | $97.88 | $59.06 |
52-Week Low | $69.77 | $26.94 |
Enterprise Value | $286.18B | $7.84B |
Dividend Yield | 2.91% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NextEra Energy (NEE) trades at $85.45, up 0.89% today, amid a bearish technical signal but strong analyst support. The stock shows robust fundamentals with a 32.4% net income margin and 17.23% ROE, though recent cash flow volatility and rising debt-to-asset ratios (47.6% in 2025) pose concerns. Positive sentiment is driven by AI-driven power demand, highlighted by a $100 billion data center partnership with Brookfield announced on July 29, 2026.
Outlook remains favorable with a consensus price target of $100.40, implying 17.5% upside, supported by 66.66% analyst buy ratings. Key opportunities include AI infrastructure growth and dividend stability, while risks involve high capital expenditures and interest rate sensitivity. Earnings momentum is mixed, with Q1 and Q2 2026 beats offset by a Q4 2025 miss.
TG Therapeutics (TGTX) trades at $49.66, up 1.02% on the day, with a bearish technical signal and recent earnings misses despite strong revenue growth. The company reported Q2 2026 revenue of $240 million and raised full-year BRIUMVI guidance to $950 million, but net income was impacted by manufacturing investments. Valuation ratios show a high P/E of 18.22 and EV/EBITDA of 56.26, while profitability metrics like ROE of 100.28% remain robust.
Outlook is mixed: strong product demand and raised revenue targets support growth, but earnings volatility and a bearish technical trend pose risks. Analyst consensus is bullish with an $63.75 price target, though legal investigations and competitive pressures require monitoring for stock investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About NextEra Energy, Inc.
NextEra Energy's regulated utility, Florida Power & Light, distributes power to more than 5 million customers in Florida. FP&L contributes more than 60% of the group's operating earnings. The renewable energy segment generates and sells power throughout the United States and Canada. Consolidated generation capacity totals more than 50 gigawatts and includes natural gas, nuclear, wind, and solar assets.
Read more on NEE →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
